- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07944053
Group Antenatal Healthcare, Education, and Recovery (GATHER)
The objective is to evaluate implementation strategies and effectiveness of group prenatal care for women in treatment for opioid use disorder.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Taylor Carrubba
- Phone Number: 215-955-8429
- Email: taylor.carrubba@jefferson.edu
Study Contact Backup
- Name: Vanessa Short
- Phone Number: 215-955-8429
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Recruiting
- Thomas Jefferson University
-
Contact:
- Taylor Carrubba
- Phone Number: 215-955-8429
- Email: taylor.carrubba@jefferson.edu
-
Principal Investigator:
- Vanessa Short, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- at least 18 years of age
- pregnant and less than 28 weeks of gestation at study enrollment
- receiving treatment for OUD
- no major antepartum complications
- capable of giving informed consent
- willing to be visited by research personnel for up to 12 months post-delivery.
Exclusion Criteria:
- inability to speak English
- medical complications of pregnancy which would preclude participation in group care.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Group Prenatal Care
group prenatal care |
Patients will be grouped with other women who are all due to deliver around the same time and receive their routine PNC together during 2-hour group sessions. During the first 30-60 minutes of each group session, patients will measure and record their own weight and blood pressure, and an OB healthcare provider (facilitator) will conduct a brief physical assessment in a private area. This 1-on-1 time is also used for the patient to discuss any private concerns that the patient does not feel to disclose to the group. Following the individual health assessments, the OB provider, co-facilitators, and patients will sit in circle for a discussion. There are a range of educational topics set for each of the ten group sessions, and the content is generally tailored to the participants' gestational age or the age of their infants. Any required blood draws and immunizations will be given at the last 30 minutes of the session, if applicable. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maternal healthcare engagement
Time Frame: from enrollment to delivery
|
Proportion of expected PNC visit attended |
from enrollment to delivery
|
|
OUD treatment retention
Time Frame: from enrollment to delivery
|
OUD treatment retention |
from enrollment to delivery
|
|
Opioid abstinence
Time Frame: from enrollment to delivery
|
Percentage of urine/blood/saliva toxicology testing negative for unauthorized opioids and other drugs during pregnancy |
from enrollment to delivery
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2026-15 TJU
- 083-CC101702-Z19603 (Other Grant/Funding Number: Westat)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.